These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 20128552)
21. Ptosis as a feature of late-onset glycogenosis type II. Groen WB; Leen WG; Vos AM; Cruysberg JR; van Doorn PA; van Engelen BG Neurology; 2006 Dec; 67(12):2261-2. PubMed ID: 17190962 [No Abstract] [Full Text] [Related]
23. Late-onset Pompe disease in a 54 year-old sportsman with an episode of syncope: a case report. Walczak-Galezewska M; Skrypnik D; Szulinska M; Musialik K; Skrypnik K; Bogdanski P Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3665-3667. PubMed ID: 28925476 [TBL] [Abstract][Full Text] [Related]
24. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961 [TBL] [Abstract][Full Text] [Related]
25. Should patients with asymptomatic pompe disease be treated? A nationwide study in France. Echaniz-Laguna A; Carlier RY; Laloui K; Carlier P; Salort-Campana E; Pouget J; Laforet P Muscle Nerve; 2015 Jun; 51(6):884-9. PubMed ID: 25786784 [TBL] [Abstract][Full Text] [Related]
26. Obstructive sleep apnea in late-onset Pompe disease treated by enzyme replacement therapy. Bhui R; Spector AR Neuromuscul Disord; 2020 Apr; 30(4):329-330. PubMed ID: 32173248 [TBL] [Abstract][Full Text] [Related]
27. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme]. Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145 [TBL] [Abstract][Full Text] [Related]
28. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291 [TBL] [Abstract][Full Text] [Related]
29. Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years. Schänzer A; Görlach J; Claudi K; Hahn A Neuromuscul Disord; 2019 Jun; 29(6):477-482. PubMed ID: 31101460 [TBL] [Abstract][Full Text] [Related]
30. Resolution of severe cardiomyopathy in infantile Pompe disease. Parent JJ; Schamberger M Cardiol Young; 2015 Jan; 25(1):146-8. PubMed ID: 25544546 [TBL] [Abstract][Full Text] [Related]
31. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. Spiridigliozzi GA; Heller JH; Kishnani PS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038 [TBL] [Abstract][Full Text] [Related]
34. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258 [TBL] [Abstract][Full Text] [Related]
35. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277 [TBL] [Abstract][Full Text] [Related]
36. Surgery for ptosis and strabismus in ocular myopathy. Zauberman H; Nawratzki I; Magora A Ophthalmologica; 1970; 161(5):477-83. PubMed ID: 5495527 [No Abstract] [Full Text] [Related]